On May 31, 2019 Jiangsu Hengrui Medicine reported China regulators approved its PD-1 drug, camrelizumab, as a third-line treatment for recurrent or refractory classical Hodgkin’s lymphoma (Press release, ChinaBio, MAY 31, 2019, View Source [SID1234556331]). Camrelizumab is the third domestic PD-1/PD-L1 drug approved in China; previously, Junshi’s Tuoyi and Innovent’s Tyvyx were granted marketing approvals. Two US-based companies have also entered China’s PD-1/PD-L1 market — Merck with Keytruda (also for melanoma) and Bristol Myers Squibb with Opdivo. Hengrui said it is testing camrelizumab in about 20 China clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!